New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
08:10 EDTRCPTReceptos risk/reward attractive following data, says Leerink
Leerink believes the Phase II data for RPC-1063 suggests the drug is meaningfully differentiated from other therapies in development at least for patients with relapsing forms of multiple sclerosis. The firm reiterates an Outperform rating on shares of Receptos with a $75 price target and views the risk/reward as attractive.
News For RCPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 5, 2015
13:01 EDTRCPTNomura sees more M&A following AbbVie's acquisition of Pharmacyclics
Nomura believes AbbVie's (ABBV) acquisition of Pharmacyclics (PCYC) supports its call that Receptos (RCPT) and Infinity Pharmaceuticals (ICPT) are on the top of M&A lists given both companies have potential $5B in peaks sales potential and unencumbered assets. Additionally, the firm believes the deal has positive implications for Neutral rated Incyte (INFI) given the potential AbbVie can now evaluate ABT-199 in combination with Incyte's duvelisib and Pharmacyclic's Imbruviea across a range of hematological malignancies.
March 4, 2015
10:37 EDTRCPTReceptos price target raised to $201 from $160 at Wedbush
Subscribe for More Information
March 3, 2015
16:05 EDTRCPTReceptos sees moving forward with Phase 3 program in ulcerative colitis
Subscribe for More Information
16:04 EDTRCPTReceptos reports Q4 EPS ($1.32), consensus ($1.19)
Subscribe for More Information
15:20 EDTRCPTNotable companies reporting after market close
Subscribe for More Information
February 23, 2015
08:41 EDTRCPTReceptos to hold a conference call
Subscribe for More Information
08:14 EDTRCPTReceptos data positive, says BMO Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use